| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1470-2045(11)70141-3 |
| P698 | PubMed publication ID | 21958503 |
| P50 | author | Peter Boyle | Q2074086 |
| Murray Brennan | Q18977783 | ||
| Tito Fojo | Q89148742 | ||
| John Zalcberg | Q89468021 | ||
| Ian F. Tannock | Q106114426 | ||
| Guy Storme | Q110644166 | ||
| Dirk Verellen | Q77648055 | ||
| Silvia Camporesi | Q79763044 | ||
| Philippe Autier | Q37840960 | ||
| Eitan Amir | Q37841237 | ||
| Richard Sullivan | Q42337438 | ||
| Alexander Eggermont | Q28317101 | ||
| Peter Naredi | Q56434665 | ||
| Rodney J. Hicks | Q43224607 | ||
| P2093 | author name string | David Taylor | |
| David Meltzer | |||
| Kevin A Schulman | |||
| Mark De Ridder | |||
| Matti Aapro | |||
| David Kerr | |||
| Neal J Meropol | |||
| David P Carbone | |||
| David Khayat | |||
| Jeffrey Peppercorn | |||
| Michael L Steinberg | |||
| Peter J Ell | |||
| Bradford R Hirsch | |||
| Karol Sikora | |||
| Arnie D Purushotham | |||
| Susan A McCloskey | |||
| Jim Siderov | |||
| Steve Williamson | |||
| Jan Geissler | |||
| Terence Roberts | |||
| Paul Catchpole | |||
| J Gordon McVie | |||
| Nancy G Brinker | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| Initial sequencing and analysis of the human genome | Q21045365 | ||
| American Society of Clinical Oncology Statement: Toward Individualized Care for Patients With Advanced Cancer | Q22241672 | ||
| Medical Bankruptcy in the United States, 2007: Results of a National Study | Q22252535 | ||
| National Institute for Clinical Excellence and its value judgments | Q24562214 | ||
| Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial | Q24605205 | ||
| Core signaling pathways in human pancreatic cancers revealed by global genomic analyses | Q24606006 | ||
| National costs of the medical liability system | Q24609590 | ||
| Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. | Q27824811 | ||
| Cancer statistics, 2010 | Q27860525 | ||
| Sipuleucel-T immunotherapy for castration-resistant prostate cancer | Q27860648 | ||
| Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects | Q28200181 | ||
| The price of innovation: new estimates of drug development costs | Q28212140 | ||
| Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction | Q28215716 | ||
| Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer | Q28240089 | ||
| Emerging lessons from the drug effectiveness review project | Q28244677 | ||
| Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer | Q28248065 | ||
| Letting the genome out of the bottle--will we get our wish? | Q28264215 | ||
| A strategy for health care reform--toward a value-based system | Q83990538 | ||
| Comparison of approaches for estimating incidence costs of care for colorectal cancer patients | Q84080710 | ||
| Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization | Q84094992 | ||
| Practice patterns and guideline adherence of medical oncologists in managing patients with early breast cancer | Q84299574 | ||
| Evidence that consumers are skeptical about evidence-based health care | Q84351572 | ||
| We have met the enemy and he is us! | Q84465763 | ||
| Physicians' views on defensive medicine: a national survey | Q84493244 | ||
| Assessing the appropriateness of care--its time has come | Q84507035 | ||
| Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firms | Q84551838 | ||
| Helping poorer countries make locally informed health decisions | Q84576225 | ||
| Growing calls in United States, Europe to improve regulation of genetic testing | Q84649741 | ||
| Comparative effectiveness research: what it means for radiology | Q84968427 | ||
| Implications of comparative effectiveness research for radiation oncology | Q87533674 | ||
| Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer | Q73668432 | ||
| Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma | Q74733433 | ||
| A method for the detailed assessment of the appropriateness of medical technologies | Q77661056 | ||
| Costs of health care: a lopsided debate | Q77923000 | ||
| The impact of state laws limiting malpractice damage awards on health care expenditures | Q79816079 | ||
| Health technology assessment of PET in oncology: re Eur J Nucl Med Mol Imaging 2003; 30:637-641 | Q80057429 | ||
| Coverage options for promising technologies: Medicare's 'coverage with evidence development' | Q80244066 | ||
| UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters | Q80865711 | ||
| What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? | Q80944346 | ||
| Criteria for deciding cost-effectiveness for expensive new anti-cancer agents | Q81099562 | ||
| Information on cost-effectiveness: an essential product of a national comparative effectiveness program | Q81285749 | ||
| A policy approach to the development of molecular diagnostic tests | Q82349672 | ||
| What is the value of oncology medicines? | Q82349681 | ||
| Late-stage cancer detection in the USA is costing lives | Q82731795 | ||
| Reforming health care reform in the 112th Congress | Q82807575 | ||
| Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions | Q82845146 | ||
| Patient access schemes for high-cost cancer medicines | Q82884089 | ||
| From bedside to bench to bedside to clinical practice: an odyssey with irinotecan | Q82903015 | ||
| NICE and the challenge of cancer drugs | Q83181791 | ||
| Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin | Q83195720 | ||
| Where's the value in health care? | Q83321238 | ||
| Concerns about Provenge simmer as CMS ponders coverage | Q83389488 | ||
| Despite steep costs, payments for new cancer drugs make economic sense | Q83557672 | ||
| Designing transparency systems for medical care prices | Q83571277 | ||
| Integrating care through bundled payments--lessons from The Netherlands | Q83629967 | ||
| Future supply and demand for oncologists : challenges to assuring access to oncology services | Q37476525 | ||
| Bystander effects and their implications for clinical radiotherapy | Q37489313 | ||
| Proton beam therapy and the convoluted pathway to incorporating emerging technology into routine medical care in the United States | Q37578236 | ||
| Systematic review of economic evidence for the detection, diagnosis, treatment, and follow-up of colorectal cancer in the United Kingdom | Q37618995 | ||
| Management of the neck after chemoradiotherapy for head and neck cancers in Asia: consensus statement from the Asian Oncology Summit 2009. | Q37625438 | ||
| American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility | Q37672016 | ||
| Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. | Q37681223 | ||
| Proton radiation in the management of localized cancer | Q37705368 | ||
| Imaging in radiation oncology: a perspective. | Q37736122 | ||
| Patient-Centered Outcomes Research Institute: the intersection of science and health care | Q37767319 | ||
| A Review of the Clinical Evidence for Intensity-modulated Radiotherapy | Q37776778 | ||
| Expansion of cancer care and control in countries of low and middle income: a call to action | Q37779973 | ||
| Cancer risk diversity in non-western migrants to Europe: An overview of the literature | Q37789068 | ||
| Fighting against age discrimination in clinical trials. | Q37791608 | ||
| Cost effectiveness of pharmacogenomics: a critical and systematic review. | Q37799352 | ||
| Robot-assisted radical cystectomy versus open radical cystectomy: a complete cost analysis | Q37814637 | ||
| Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction? | Q37822199 | ||
| Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? | Q37822201 | ||
| Value and cancer care: toward an equitable future | Q37822206 | ||
| Advances in cancer therapeutics and patient access to new drugs. | Q37823895 | ||
| Genomics and the continuum of cancer care | Q37832479 | ||
| A review of economic evaluations of genetic testing services and interventions (2004-2009). | Q37832922 | ||
| Listening to Provenge--what a costly cancer treatment says about future Medicare policy | Q39763380 | ||
| Access with evidence development: the US experience | Q39908685 | ||
| American Society of Clinical Oncology guidance statement: the cost of cancer care | Q39965070 | ||
| PET/MRI: a different spin from under the rim. | Q40016365 | ||
| The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry | Q40027009 | ||
| Are patients in clinical trials representative of the general population? Dose intensity and toxicities associated with FE100C-D chemotherapy in a non-trial population of node positive breast cancer patients compared with PACS-01 trial group | Q40342751 | ||
| Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. | Q40482876 | ||
| Macrophages enhance the radiosensitizing activity of lipid A: a novel role for immune cells in tumor cell radioresponse. | Q40513405 | ||
| A rational framework for decision making by the National Institute For Clinical Excellence (NICE). | Q40632683 | ||
| A meta-analysis of thoracic radiotherapy for small-cell lung cancer | Q41086687 | ||
| Cost-effectiveness of PET imaging in clinical oncology | Q41240148 | ||
| A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer | Q28297827 | ||
| Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial | Q28305038 | ||
| Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer | Q28305293 | ||
| Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer | Q28308193 | ||
| Why do we love medicines so much? An evolutionary perspective on the human love of pills, potions and placebo | Q28749741 | ||
| Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials | Q29031162 | ||
| The Path to Personalized Medicine | Q29541502 | ||
| Replication validity of genetic association studies | Q29615456 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 | ||
| Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study | Q29619653 | ||
| Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer | Q29620038 | ||
| The uncritical use of high-tech medical imaging | Q30451164 | ||
| Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. | Q31130672 | ||
| Bayesian propensity score analysis for observational data | Q33384686 | ||
| Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival | Q33515519 | ||
| Making cost assessments based on RCTs more useful to decision-makers | Q33571771 | ||
| Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study | Q33709566 | ||
| End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences | Q33710987 | ||
| Health care costs in the last week of life: associations with end-of-life conversations | Q33822940 | ||
| Development of WHO guidelines on generalized cost-effectiveness analysis | Q33903387 | ||
| Understanding how out-of-pocket expenses, treatment value, and patient characteristics influence treatment choices | Q33942677 | ||
| Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies | Q34002537 | ||
| Stereotactic body radiation therapy for inoperable early stage lung cancer | Q34010065 | ||
| Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET | Q34041370 | ||
| Stereotactic body radiation therapy in multiple organ sites | Q36756959 | ||
| Primary extraosseous Ewing sarcoma of the lung in children | Q36791086 | ||
| Cancer's next frontier: addressing high and increasing costs | Q36824884 | ||
| What if the federal government negotiated pharmaceutical prices for seniors? An estimate of national savings | Q36841041 | ||
| Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer | Q36900261 | ||
| Breast cancer in elderly women. Optimizing the treatment | Q36939312 | ||
| The impact of insurance on access to cancer clinical trials at a comprehensive cancer center | Q37023806 | ||
| The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. | Q37111658 | ||
| Evolution of the randomized controlled trial in oncology over three decades | Q37117089 | ||
| Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? | Q37126136 | ||
| How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question | Q37300032 | ||
| A changing paradigm in the study and adoption of emerging health care technologies: coverage with evidence development | Q37309734 | ||
| Off-label use of anticancer drugs | Q37326851 | ||
| Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies | Q37337123 | ||
| Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes | Q37378223 | ||
| 10 years of NICE: still growing and still controversial | Q37430847 | ||
| Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors | Q34095686 | ||
| Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer | Q34106818 | ||
| An official American Thoracic Society systematic review: insurance status and disparities in lung cancer practices and outcomes | Q34147421 | ||
| Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. | Q34155828 | ||
| Deconstructing the drug development process: the new face of innovation | Q34190877 | ||
| The burden of illness of cancer: economic cost and quality of life | Q34198603 | ||
| High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. | Q34266149 | ||
| Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation | Q34315833 | ||
| Defensive medicine among high-risk specialist physicians in a volatile malpractice environment | Q34422822 | ||
| Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology | Q34560071 | ||
| Clinical role of positron emission tomography in oncology | Q34570065 | ||
| Estimates of the cancer incidence and mortality in Europe in 2006. | Q34575047 | ||
| Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review | Q34610692 | ||
| Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. | Q34624122 | ||
| Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis | Q34659767 | ||
| Innovations in image-guided radiotherapy. | Q34717651 | ||
| Projections of the cost of cancer care in the United States: 2010-2020. | Q35022830 | ||
| Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). | Q35045467 | ||
| Applications of positron emission tomography in the development of molecular targeted cancer therapeutics | Q35537860 | ||
| American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. | Q35613883 | ||
| Evaluation of trends in the cost of initial cancer treatment | Q35820277 | ||
| A sense of danger from radiation. | Q35820333 | ||
| Generalisability in economic evaluation studies in healthcare: a review and case studies. | Q35950554 | ||
| Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model | Q36157329 | ||
| Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report | Q36263674 | ||
| Economic implications of potential changes to regulatory and reimbursement policies for medical devices | Q36293520 | ||
| Economic analyses of human genetics services: a systematic review | Q36296074 | ||
| 21 years of biologically effective dose | Q36324701 | ||
| Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies | Q36466906 | ||
| TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? | Q36525365 | ||
| Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial | Q36610798 | ||
| Patient time costs associated with cancer care | Q36698752 | ||
| Cost of cancer care: issues and implications | Q36702504 | ||
| European perspective on the costs and cost-effectiveness of cancer therapies | Q36702508 | ||
| EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. | Q55051385 | ||
| Need for global action for cancer control | Q56994804 | ||
| Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study | Q57192409 | ||
| How can we tell if PET imaging for cancer is cost effective? | Q57758872 | ||
| FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer | Q57758918 | ||
| Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98 | Q58466062 | ||
| Translating cancer research into targeted therapeutics | Q59060386 | ||
| Translational research: Crossing the valley of death | Q59063636 | ||
| Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin | Q59364974 | ||
| Introduction: The prevention agenda | Q60065164 | ||
| Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators | Q61698715 | ||
| Assessing the economic challenges posed by orphan drugs | Q64046068 | ||
| Cancer treatment cost in the United States: has the burden shifted over time? | Q64130430 | ||
| Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial | Q66829419 | ||
| NICE system...shame about the side-effects | Q73228042 | ||
| Nuclear medicine and thyroid cancer | Q73362487 | ||
| Oncologists judge themselves the best judges of cancer treatments | Q73635104 | ||
| The risk of exaggerated risk aversion-a life and death struggle for molecular imaging | Q42578280 | ||
| The impact of the 'Clinical Trials' directive on the cost and conduct of non-commercial cancer trials in the UK. | Q42604144 | ||
| Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial | Q42606697 | ||
| Comparative effectiveness of minimally invasive vs open radical prostatectomy. | Q42636571 | ||
| Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial | Q42801121 | ||
| Cetuximab Monotherapy in Patients with Advanced Non-small Cell Lung Cancer After Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy | Q42848018 | ||
| Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial | Q43121565 | ||
| Health technology assessment and cancer imaging: who should be setting the agenda? | Q43183480 | ||
| Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study | Q43206204 | ||
| Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen | Q43233449 | ||
| Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients | Q43681440 | ||
| New Technology and Health Care Costs — The Case of Robot-Assisted Surgery | Q43706841 | ||
| Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up | Q44071678 | ||
| A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer | Q44093928 | ||
| Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs | Q44335100 | ||
| Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer | Q44381576 | ||
| Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay | Q44995510 | ||
| Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America | Q45382453 | ||
| Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. | Q45999177 | ||
| Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. | Q46027726 | ||
| Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. | Q46068571 | ||
| The overthrow of the (evidence) hierarchy | Q46367486 | ||
| Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006. | Q46435513 | ||
| Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. | Q46466435 | ||
| Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. | Q46942430 | ||
| Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100. | Q46968093 | ||
| Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? | Q46974051 | ||
| Commentary: health care technology and medical education: putting physical diagnosis in its proper place | Q47262780 | ||
| Discounting the value of life | Q48680952 | ||
| Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial | Q48730138 | ||
| Equipoise lost: ethics, costs, and the regulation of cancer clinical research | Q48830240 | ||
| Going off-label without venturing off-course: evidence and ethical off-label prescribing | Q48971133 | ||
| Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial | Q49072518 | ||
| Out-of-pocket health-care expenditures among older Americans with cancer. | Q50744572 | ||
| Joint project of the International Network of Agencies for Health Technology Assessment--Part 2: Managing the diffusion of positron emission tomography with health technology assessment. | Q50779357 | ||
| Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. | Q51060956 | ||
| Trends in underinsurance and the affordability of employer coverage, 2004-2007. | Q51132807 | ||
| Degradation of the Bragg peak due to inhomogeneities. | Q51658507 | ||
| De Testimonio: on the evidence for decisions about the use of therapeutic interventions. | Q51942363 | ||
| Effects of cost sharing on care seeking and health status: results from the Medical Outcomes Study. | Q51962348 | ||
| VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. | Q53260567 | ||
| Are health economics making us sick? | Q53265714 | ||
| Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. | Q53477419 | ||
| Cost of care for elderly cancer patients in the United States. | Q53730492 | ||
| Early accelerated approval for highly targeted cancer drugs. | Q54601901 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 933-980 | |
| P577 | publication date | 2011-09-01 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Delivering affordable cancer care in high-income countries | |
| P478 | volume | 12 |
| Q34621791 | 'Burden to others' as a public concern in advanced cancer: a comparative survey in seven European countries |
| Q91879266 | 360 Health Analysis (H360) - A Proposal for an Integrated Vision of Breast Cancer in Portugal |
| Q38062952 | A 'year in the life' of health services research in oncology |
| Q93006463 | A Comprehensive Review of Calcium Electroporation -A Novel Cancer Treatment Modality |
| Q47203111 | A National Budget Impact Analysis of a Specialised Surveillance Programme for Individuals at Very High Risk of Melanoma in Australia. |
| Q91970770 | A New Method for Ethical and Efficient Evidence Generation for Off-Label Medication Use in Oncology (A Case Study in Glioblastoma) |
| Q28079810 | A Review on Cost-Effectiveness and Cost-Utility of Psychosocial Care in Cancer Patients |
| Q37644553 | A catalyst for change: the European cancer Patient's Bill of Rights |
| Q48357233 | A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer |
| Q34029999 | A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer |
| Q28079625 | A critical review of recent developments in radiotherapy for non-small cell lung cancer |
| Q27005964 | A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer |
| Q27008869 | A systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancer |
| Q36566120 | AIDS and HIV Infection after Thirty Years |
| Q49069138 | Access to innovative radiotherapy: how to make it happen from an economic perspective? |
| Q57109294 | Accuracy of administrative databases in detecting primary breast cancer diagnoses: a systematic review |
| Q86911556 | Actual costs of cancer drugs in 15 European countries |
| Q43903120 | Advanced stage diagnosis of cancer: who is at greater risk? |
| Q37383668 | Advancing comparative studies of patterns of care and economic outcomes in cancer: challenges and opportunities |
| Q57906950 | Affordable cancer care |
| Q61896769 | Affordable cancer care: pipedream or achievable reality? |
| Q61896807 | Analysis of media reporting of The Lancet Oncology Commission |
| Q48005672 | Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan |
| Q26864696 | Applying what we know to accelerate cancer prevention |
| Q38152942 | Appraising iniparib, the PARP inhibitor that never was--what must we learn? |
| Q38032867 | Are cancer trials valid and useful for the general surgeon and surgical oncologist? |
| Q39675893 | Are the large pharmaceutical and biotechnology companies driving the discovery, research and development of targeted cancer therapies? |
| Q39747965 | Association of Palliative Care Consultation With Reducing Inpatient Chemotherapy Use in Elderly Patients With Cancer in Japan: Analysis Using a Nationwide Administrative Database |
| Q57161094 | Automation in intensity modulated radiotherapy treatment planning-a review of recent innovations |
| Q55279429 | Availability and affordability of biologic versus non-biologic anticancer medicines: a cross-sectional study in Punjab, Pakistan. |
| Q89986560 | Barriers and Facilitators to De-Implementation of the Choosing Wisely® Guidelines for Low-Value Breast Cancer Surgery |
| Q38302729 | Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective? |
| Q33872841 | Beyond Me, Too. |
| Q31139104 | Big Data in radiation therapy: challenges and opportunities |
| Q34978199 | Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain |
| Q64234421 | Cancer Core Europe: A translational research infrastructure for a European mission on cancer |
| Q83190961 | Cancer care after the National Health Service reforms |
| Q35714571 | Cancer care burden: aiming at the Achilles heel |
| Q35736059 | Cancer care coordinators in stage III colon cancer: a cost-utility analysis |
| Q86687766 | Cancer control in Latin America and the Caribbean: a bold ambition? |
| Q88477672 | Cancer cost communication: experiences and preferences of patients, caregivers, and oncologists-a nationwide triad study |
| Q38684256 | Cancer costs and outcomes in the Finnish population 2004-2014. |
| Q92946963 | Cancer drug development: The missing links |
| Q40209626 | Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study |
| Q61896761 | Cancer research in India: national priorities, global results |
| Q38172320 | Cancer survival: global surveillance will stimulate health policy and improve equity |
| Q87369852 | Cancer-treatment toxicity: can nutrition help? |
| Q58088055 | CancerCostMod: a model of the healthcare expenditure, patient resource use, and patient co-payment costs for Australian cancer patients |
| Q85014629 | Caring for patients with haematological malignancies |
| Q36068256 | Catastrophic Health Care Expenditure among Older People with Chronic Diseases in 15 European Countries |
| Q37392449 | Challenges of radiation oncology in Spain today |
| Q60679751 | Challenges related to palliative care |
| Q30241794 | Changing global policy to deliver safe, equitable, and affordable care for women's cancers |
| Q56582377 | Chemotherapy Administration |
| Q55302677 | Chemotherapy and palliative care near end-of life: examining the appropriateness at a cancer institute for colorectal cancer patients. |
| Q90299761 | Choosing wisely in oncology: necessity and obstacles |
| Q37458781 | Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology |
| Q37959798 | Comparing how significantly the pharmacological treatment of genitourinary cancer in a non-curative setting affects endpoints of survival or response |
| Q33611198 | Contextualizing the use of oncologic imaging within treatment phases: imaging trends and modality preferences, 2000-2014. |
| Q91050887 | Core elements of national cancer control plans: a tool to support plan development and review |
| Q36138377 | Cost and effectiveness of image-guided radiotherapy for non-operated localized lung cancer: a population-based propensity score-matched analysis |
| Q34618694 | Cost effectiveness after a pancreaticoduodenectomy: bolstering the volume argument. |
| Q41559005 | Cost of HAART in Italy: multicentric evaluation and determinants from a large HIV outpatient cohort. |
| Q36260314 | Cost of breast cancer based on real-world data: a cancer registry study in Italy |
| Q31075231 | Cost of care for cancer patients in England: evidence from population-based patient-level data |
| Q34699421 | Cost of illness in colorectal cancer: an international review |
| Q34798586 | Cost profiles of colorectal cancer patients in Italy based on individual patterns of care. |
| Q39141802 | Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries |
| Q36417749 | Cost, coverage, and comparative effectiveness research: the critical issues for oncology |
| Q37704152 | Cost-effectiveness analysis of an 18-week exercise programme for patients with breast and colon cancer undergoing adjuvant chemotherapy: the randomised PACT study |
| Q38469815 | Cost-effectiveness analysis of axitinib through a probabilistic decision model |
| Q53563765 | Cost-effectiveness and sustainability of breast cancer screening and new anti-cancer drugs. |
| Q33558630 | Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer |
| Q36439424 | Cost-effectiveness of chemotherapy combined with thoracic radiotherapy versus chemotherapy alone for limited stage small cell lung cancer: A population-based propensity-score matched analysis |
| Q36840375 | Cost-effectiveness of neoadjuvant concurrent chemoradiotherapy versus esophagectomy for locally advanced esophageal squamous cell carcinoma: A population-based matched case-control study |
| Q44383576 | Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia |
| Q36841028 | Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. |
| Q37278390 | Delivering high-quality and affordable care throughout the cancer care continuum |
| Q87305797 | Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care |
| Q38398438 | Delivery of affordable and equitable cancer care in India |
| Q39109249 | Determinants of utilisation differences for cancer medicines in Belgium, Scotland and Sweden |
| Q61896699 | Developing institutions for cancer care in low-income and middle-income countries: from cancer units to comprehensive cancer centres |
| Q35198347 | Development and economic trends in cancer therapeutic drugs: a 5-year update 2010-2014. |
| Q54522529 | Discussing and prescribing expensive unfunded anticancer drugs in Australia. |
| Q36235751 | Does a too risk-averse approach to the implementation of new radiotherapy technologies delay their clinical use? |
| Q46842669 | Does comparative effectiveness research promote rationing of cancer care? |
| Q41062025 | Does hospital need more hospice beds? Hospital charges and length of stays by lung cancer inpatients at their end of life: A retrospective cohort design of 2002-2012. |
| Q35678127 | Does the cancer drugs fund lead to faster uptake of cost-effective drugs? A time-trend analysis comparing England and Wales |
| Q83190957 | Drivers of the cost of cancer care |
| Q33895530 | Drug assessment by a Pharmacy and Therapeutics committee: from drug selection criteria to use in clinical practice |
| Q35089146 | Drug waste minimization as an effective strategy of cost-containment in oncology |
| Q41313977 | Drugs for solid cancer: the productivity crisis prompts a rethink |
| Q35223735 | Drugs, cancer and end-of-life care: a case study of pharmaceuticalization? |
| Q54836371 | ESMO Open-Cancer Horizons and the future of oncology. |
| Q43937749 | Economic burden of cancer across the European Union: a population-based cost analysis |
| Q39813228 | Economic burden of gastrointestinal cancer under the protection of the New Rural Cooperative Medical Scheme in a region of rural China with high incidence of oesophageal cancer: cross-sectional survey |
| Q36138536 | Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC). |
| Q37645248 | Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis |
| Q37252482 | Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia |
| Q37383663 | Economic studies in colorectal cancer: challenges in measuring and comparing costs. |
| Q26823075 | Effective coverage: a metric for monitoring Universal Health Coverage |
| Q36483188 | Effectiveness of multidimensional cancer survivor rehabilitation and cost-effectiveness of cancer rehabilitation in general: a systematic review. |
| Q90100076 | Elevated Hexokinase II Expression Confers Acquired Resistance to 4-Hydroxytamoxifen in Breast Cancer Cells |
| Q64069023 | End-of-life cost and its determinants for cancer patients in urban China: a population-based retrospective study |
| Q38945180 | Escalating Health Care Expenditures in Cancer Decedents' Last Year of Life: A Decade of Evidence from a Retrospective Population-Based Cohort Study in Taiwan |
| Q37689561 | Ethical Hurdles in the Prioritization of Oncology Care |
| Q43792807 | Evaluating the place of 18-fluoro-2-deoxy-D-glucose positron emission tomography scanning in primary staging and beyond in patients with follicular lymphoma. |
| Q47952534 | Evaluation of novel radiotherapy technologies: what evidence is needed to assess their clinical and cost effectiveness, and how should we get it? |
| Q34339066 | Evaluation of the duplication of staging CT scans for localized colon cancer in a Medicare population |
| Q36416574 | Evaluation of the utilization of external radiotherapy in the treatment of localized prostate cancer in Andalusia, Spain |
| Q61896771 | Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries |
| Q90656950 | Expanding Access to Essential Quality Services for Cancer Patients as Part of Universal Health Coverage: Reflections From the World Cancer Leaders' Summit |
| Q33617879 | Expenditure and financial burden for the diagnosis and treatment of colorectal cancer in China: a hospital-based, multicenter, cross-sectional survey |
| Q39330867 | Final transitions to place of death: patients and families wishes |
| Q42319245 | Financial Toxicity and Societal Costs of Cancer Care: Distinct Problems Require Distinct Solutions |
| Q36720148 | First do no harm: evidence sometimes shows the self-evident to be wrong |
| Q38096573 | First do no harm: the review frequency of illness depends as much on family dynamics as on material factors |
| Q38081462 | Funding UK cancer care: time for a level playing field? |
| Q36336227 | GUCY2C molecular staging personalizes colorectal cancer patient management |
| Q35029538 | Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE). |
| Q30873972 | Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). |
| Q48507831 | Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. |
| Q37058000 | Guidelines: usefulness and limitations |
| Q38103647 | Has the time come for metronomics in low-income and middle-income countries? |
| Q35776197 | Health care costs: how do we decide value? When do we decide? How do we particularize the decisions? |
| Q26826505 | Health economic aspects of breast cancer treatment: the compulsory health insurances' view |
| Q38316487 | Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer |
| Q37391457 | Health economics and cost-effectiveness research with special reference to hemato-oncology |
| Q36964343 | Health service use and costs in the last 6 months of life in elderly decedents with a history of cancer: a comprehensive analysis from a health payer perspective |
| Q38130362 | Health systems performance and cancer outcomes |
| Q38255974 | Health technology assessment of cancer drugs in Canada, the United Kingdom and Australia: should the United States take notice? |
| Q34080274 | Healthcare Resource Use and Expenditures among Metastatic Breast Cancer Patients Treated with HER2-Targeted Agents |
| Q34012398 | How might healthcare systems influence speed of cancer diagnosis: a narrative review |
| Q92460048 | How public health services pay for radiotherapy in Europe: an ESTRO-HERO analysis of reimbursement |
| Q41728685 | IMPLICATIONS OF GLOBAL PRICING POLICIES ON ACCESS TO INNOVATIVE DRUGS: THE CASE OF TRASTUZUMAB IN SEVEN LATIN AMERICAN COUNTRIES. |
| Q53592000 | Immunothérapie : une innovation de rupture non soutenable économiquement ? |
| Q37392964 | Implementation of a rapid learning platform: Predicting 2-year survival in laryngeal carcinoma patients in a clinical setting |
| Q35947787 | Implementation of cancer clinical care pathways: a successful model of collaboration between payers and providers |
| Q43076068 | Implicating anaesthesia and the perioperative period in cancer recurrence and metastasis |
| Q38129974 | Importance of accessible cancer care |
| Q30235988 | Improving access to high-cost cancer drugs in Latin America: Much to be done |
| Q36195119 | Increasing Receipt of High-Tech/High-Cost Imaging and Its Determinants in the Last Month of Taiwanese Patients With Metastatic Cancer, 2001-2010: A Retrospective Cohort Study |
| Q34787152 | Indeterminate pulmonary nodules at colorectal cancer staging: a systematic review of predictive parameters for malignancy |
| Q37463523 | Initial treatment for newly diagnosed elderly colorectal cancer patients: patterns of care in Italy and the United States. |
| Q37404683 | Innovations that reach the patient: early health technology assessment and improving the chances of coverage and implementation |
| Q34246580 | Institute of medicine recommendations for improving the quality of cancer care: what do they mean for the general internist? |
| Q30684440 | Integrating patient reported outcomes with clinical cancer registry data: a feasibility study of the electronic Patient-Reported Outcomes From Cancer Survivors (ePOCS) system |
| Q24197650 | Interventions for promoting habitual exercise in people living with and beyond cancer |
| Q24198026 | Interventions for promoting habitual exercise in people living with and beyond cancer |
| Q57758848 | Is there still a role for SPECT–CT in oncology in the PET–CT era? |
| Q30367634 | John Bradshaw (1918-1989): putting doctors on trial. |
| Q52604155 | Labour force participation and the cost of lost productivity due to cancer in Australia. |
| Q33655798 | Learning from the public: citizens describe the need to improve end-of-life care access, provision and recognition across Europe |
| Q35838562 | Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development |
| Q38163486 | Market access of cancer drugs in European countries: improving resource allocation |
| Q52610761 | Medication overuse in oncology: current trends and future implications for patients and society. |
| Q55111318 | Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM). |
| Q46249376 | Migration from Mexico to the United States: A high-speed cancer transition |
| Q44404129 | Modelling the benefits of early diagnosis of pancreatic cancer using a biomarker signature |
| Q33913537 | Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups |
| Q35741765 | New Highly Active Antiretroviral drugs and generic drugs for the treatment of HIV infection: a budget impact analysis on the Italian National Health Service (Lombardy Region, Northern Italy) |
| Q36378757 | Non-muscle-invasive bladder cancer: a vision for the future |
| Q44194985 | Nuclear medicine, scientific publishing and the era of cost containment |
| Q43210863 | Out of pocket, out of sight? An unmeasured component of the burden of cancer |
| Q49843226 | Overuse in cancer care: do European studies provide information useful to support policies? |
| Q36370093 | Overuse of Health Care Services in the Management of Cancer: A Systematic Review |
| Q85014627 | Paediatric oncology: are there ways to bend the costs? |
| Q53757763 | Patient Financial Assistance Programs: A Path to Affordability or a Barrier to Accessible Cancer Care? |
| Q34457992 | Patient experience and attitudes toward addressing the cost of breast cancer care |
| Q49207085 | Pazopanib and the treatment palette for soft-tissue sarcoma |
| Q47217213 | Perioperative events influence cancer recurrence risk after surgery. |
| Q40885302 | Personalized medicine: does the molecular suit fit? |
| Q36235704 | Personalized radiotherapy: concepts, biomarkers and trial design |
| Q34938911 | Personalizing health care: feasibility and future implications |
| Q94337970 | Physical activity and exercise interventions for disease‐related physical and mental health during and following treatment in people with non‐advanced colorectal cancer |
| Q40108098 | Planning cancer control in Latin America and the Caribbean |
| Q30769871 | Point/Counterpoint. Future radiotherapy practice will be based on evidence from retrospective interrogation of linked clinical data sources rather than prospective randomized controlled clinical trials |
| Q38138821 | Position statement on ethics, equipoise and research on charged particle radiation therapy |
| Q42334166 | Preventing breast cancer now by acting on what we already know |
| Q28552507 | Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis |
| Q46647119 | Priorities for treatment, care and information if faced with serious illness: a comparative population-based survey in seven European countries |
| Q36406080 | Promise and perils of guidelines in quality cancer care |
| Q48407548 | Promises and pitfalls of new technology in radiotherapy |
| Q38376709 | Publicly funded practice-oriented clinical trials: of importance for healthcare payers |
| Q44956781 | Quantifying the burden of informal caregiving for patients with cancer in Europe |
| Q45213721 | Radioprotective effect of calcium channel blockers against late rectal bleeding in prostate cancer |
| Q59587344 | Radiotherapy capacity in Europe—time to even things out? |
| Q30854185 | Rapid learning in practice: a lung cancer survival decision support system in routine patient care data |
| Q83392370 | Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer |
| Q34105982 | Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis |
| Q53026370 | Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib. |
| Q35835158 | Realising the Value of Linked Data to Health Economic Analyses of Cancer Care: A Case Study of Cancer 2015. |
| Q35058129 | Recent trends in economic burden of acute myocardial infarction in South Korea |
| Q85014632 | Regulators, payers, and prescribers: can we fill the gaps? |
| Q57495214 | Research into end-of-life cancer care—investment is needed |
| Q30827101 | Retrospective studies of end-of-life resource utilization and costs in cancer care using health administrative data: a systematic review |
| Q26864247 | Review and uses of stereotactic body radiation therapy for oligometastases |
| Q46431337 | Revolutionising cancer care in South Africa |
| Q51241237 | Rising cost of anticancer drugs in Australia. |
| Q56383753 | Risk-related F-FDG PET/CT and new diagnostic strategies in patients with solitary pulmonary nodule: the ITALIAN multicenter trial |
| Q47151262 | Rituximab biosimilar evaluated by network meta-analysis. |
| Q38853093 | S-Adenosylmethionine Affects ERK1/2 and Stat3 Pathways and Induces Apotosis in Osteosarcoma Cells. |
| Q93016765 | SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer |
| Q49017504 | Segmental 18F-FDG-PET/CT in a single pulmonary nodule: a better cost/effectiveness strategy |
| Q44898207 | Should be NICE have a Spanish NICE? |
| Q36286485 | Should positron emission tomography/computed tomography be the first rather than the last test performed in the assessment of cancer? |
| Q26781045 | Specialist palliative care services for adults with advanced, incurable illness in hospital, hospice, or community settings--protocol for a systematic review |
| Q31032455 | Standardized data collection to build prediction models in oncology: a prototype for rectal cancer |
| Q85014619 | Striking a balance between idealism and fatalism |
| Q38765324 | Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma |
| Q98568375 | Supportive Care: An Indispensable Component of Modern Oncology |
| Q38057088 | Supportive, palliative, and end-of-life care for patients with cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2012. |
| Q48448506 | Targeted therapies: Manufacturer sponsorship bias in economic analyses matters |
| Q86866717 | The "PROCAINA (PROstate CAncer INdication Attitudes) Project" (Part II)--a survey among Italian radiation oncologists on radical radiotherapy in prostate cancer |
| Q39203304 | The Changing Health Care Landscape and Implications of Organizational Ethics on Modern Medical Practice |
| Q51334797 | The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating e |
| Q53116910 | The PROCAINA (PROstate CAncer INdication Attitudes) Project (Part I): a survey among Italian radiation oncologists on postoperative radiotherapy in prostate cancer. |
| Q38917649 | The Pharmacological Costs of Complete Liver Resections in Unselected Advanced Colorectal Cancer Patients: Focus on Targeted Agents. A Review of Randomized Clinical Trials |
| Q30205749 | The burden of disease in older people and implications for health policy and practice |
| Q37458769 | The cost of cancer care is not related to its outcomes |
| Q24187525 | The effectiveness and cost-effectiveness of inpatient specialist palliative care in acute hospitals for adults with advanced illness and their caregivers |
| Q57353764 | The effectiveness and cost-effectiveness of inpatient specialist palliative care in acute hospitals for adults with advanced illness and their caregivers |
| Q94336926 | The effectiveness and cost‐effectiveness of inpatient specialist palliative care in acute hospitals for adults with advanced illness and their caregivers |
| Q38598014 | The expanding role of primary care in cancer control. |
| Q45153508 | The feasibility of a randomised controlled trial for the axillary management of a select group of invasive breast cancer patients: SLNB vs. no-SLNB. |
| Q38255597 | The financial burden of cancer care: do patients in the US know what to expect? |
| Q44073308 | The future of predictive models in radiation oncology: from extensive data mining to reliable modeling of the results. |
| Q38282454 | The implications of out-of-pocket cost of cancer treatment in the USA: a critical appraisal of the literature |
| Q38801398 | The need for community pharmacists in oncology outpatient care: a systematic review. |
| Q86655842 | The need for economic evaluation in primary prevention of cancer |
| Q61902035 | The need to expand global access to radiotherapy |
| Q85014636 | The opportunity cost of cancer care: a statement from NICE |
| Q51440848 | The possible use of inorganic phosphate in osteosarcoma therapy. |
| Q57261297 | The rocky road to personalized medicine: computational and statistical challenges |
| Q58605622 | The role of biosimilars in value-based oncology care |
| Q30241957 | The role of the GP in follow-up cancer care: a systematic literature review |
| Q89305923 | The role of universal health coverage in reducing cancer deaths and disparities |
| Q83409508 | The state of the art in the development of biosimilars |
| Q42290525 | The value proposition of molecular medicine |
| Q38097382 | The war on cancer: are we winning? |
| Q38057179 | Therapeutic application of monoclonal antibodies in cancer: advances and challenges |
| Q88801841 | This is a call to oncologists for action |
| Q87679580 | Three countries-half of the global cancer burden |
| Q91321428 | Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspective |
| Q38522439 | Translating Regenerative Biomaterials Into Clinical Practice |
| Q47445819 | Translation in solid cancer: are size-based response criteria an anachronism? |
| Q35102711 | Translational cancer research: balancing prevention and treatment to combat cancer globally |
| Q49898379 | Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer |
| Q56897146 | Update on immune checkpoint inhibitors in lung cancer |
| Q39637230 | Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience |
| Q37167698 | Utilization of Pharmaceutical Patient and Prescription Assistance Programs via a Pharmacy Department Patient Assistance Program for Indigent Cancer Patients |
| Q35963416 | Validity of breast, lung and colorectal cancer diagnoses in administrative databases: a systematic review protocol |
| Q55262745 | Value-based procurement of prostheses for total knee replacement. |
| Q42649907 | Value: The Next Frontier in Cancer Care |
| Q47563275 | Valuing end-of-life care in the United States: the case of new cancer drugs |
| Q35756074 | Variation in performance of candidate surgical quality measures for muscle-invasive bladder cancer by hospital type |
| Q38166324 | Volume criteria for the treatment of head and neck cancer: Are they evidence based? |
| Q92269402 | What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population |
| Q48639219 | What is the future for cancer clinical trials? |
| Q83190964 | What price cure? |
| Q84975481 | [Palliative care: an example of Comparative Effectiveness Research?] |
| Q52889701 | [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology]. |
| Q84710667 | [Rationing health care by thresholds for clinical benefit and its acceptance by the German population] |
| Q46316904 | …And the only side-effects are good ones |
Search more.